In the last few years, PSMA PET has emerged as an accurate tool to detect metastatic lymph nodes (LNs), especially in patients with high risk for distant involvement at presentation or in patients showing Biochemical Recurrence (BCR) of prostate cancer, candidates or eligible for salvage lymphadenectomy11. The gene discussed is FOLH1; the disease is prostate carcinoma.